Las Vegas, NV -- (SBWIRE) -- 12/18/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Berkshire Hathaway Inc. (NYSE:BRK.A), CytRx Corporation (NASDAQ:CYTR), Cal Dive International, Inc. (NYSE:DVR), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)
Berkshire Hathaway Inc. (NYSE:BRK.A) managed to keep its fall at -0.42% on above-normal volume of 500.00 M shares. The stock settled at $ 170,420.00 after floating in a range of $ 170,375.00 to $171,151.98. Its latest price has reached market capitalization of $280.79 billion. Its 52-week range has been $132,400.00to $178,900.00. Berkshire Hathaway Inc. (Berkshire) is a holding company owning subsidiaries engaged in a number of diverse business activities.
Has BRK.A Found The Bottom and Ready To Move Up? Find Out Here
CytRx Corporation (NASDAQ:CYTR) traded down on a volume of 3.58 million, lower than its standard daily volume. Shares have dropped-3.45% to $5.04. Over the last twelve months, the stock has gained 170.97% and faced a worst price of $1.80. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology.
Has CYTR Found The Bottom And Ready To Gain Momentum? Find Out Here
Cal Dive International, Inc. (NYSE:DVR) settled -1.16% lower at $1.70 on above-normal volume of 3.40M shares during the last trading day. The stock has its 12-month high at $2.38 and 52-week low price was $1.51. It traded in a range of $1.67 to $1.75 during the last trading day. Cal Dive International, Inc. (CDI) is a marine contractor that provides manned diving, pipelay and pipe burial, platform installation and platform salvage services to a diverse customer base in the offshore oil and natural gas industry.
Will DVR Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) was up on high volume, trading at a volume of 3.26M versus its average daily volume of 1.75 million shares. At $2.17, the stock has attained market capitalization of 291.53 million. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent.
Will NAVB Continue To Move Higher? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)